

13 **Abstract:**

14 A sandwich-based electrochemical immunosensor was designed for detection of avian
15 influenza virus (AIV) strains H5N1 and H4N6. This sensor was developed using gold-graphene
16 nanocomposites, immobilized viral antibodies, and CdTe quantum dot electrochemical
17 tagging. The nanocomposites were formed by the simultaneous reduction of a gold salt and
18 graphene using hydroquinone as the reducing agent, thus producing non-spherical gold
19 nanoparticles on graphene sheets. Viral antibodies were immobilized on nanocomposites and
20 CdTe quantum dots through N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide and N-
21 hydroxysuccinimide chemistry. Cyclic voltammetry studies were used to validate the detection
22 of H5N1 surface protein and H4N6 inactivated virus. The immunosensor detected H5 protein
23 in phosphate buffer solution (pH 7.4) with a limit of detection (LOD) of 10 fg/mL and a linear
24 detection range was established for 10 ng/mL to 10 pg/mL. The biosensor detected H4N6 in
25 three parts diluted whole chicken blood with a LOD of 1.28×10^{-7} hemagglutinating units
26 (HAU). Commercial ELISA testing for H5N1 and H4N6 showed limits of detection of 10
27 ng/mL and 0.128 HAU, respectively. The sensor showed 10^6 -fold increased detection of H4N6
28 virus in blood in comparison to its commercial ELISA kit counterpart. The developed
29 immunosensor effectively change the way avian influenza is detected, monitored, and
30 controlled; transforming time-consuming reactive methods, into rapid predictive technology.

31

32 **Keywords:** Electrochemical Immunosensor, Avian Influenza, H5N1, H4N6, Nanocomposites,
33 Point-of-care

34 **1. Introduction**

35 To meet the growing demands for animal protein, global poultry production will double in
36 the next 25 years. The global poultry industry has been deeply impacted by outbreaks of avian
37 influenza virus (AIV) since the late 1990's. The Canadian poultry industry has also had its
38 share of major losses due to AIV, most notably was the 2004 outbreak in British Columbia,
39 which resulted in culling 19 million birds. Recent AIV outbreaks in British Columbia and
40 Ontario in 2015 also have caused economic losses to the Canadian poultry industry. Aside from
41 the significant impact of AIV on animal health, some of these viruses have an impact on public
42 health. AIV causes three- to five-million people to fall severely ill, resulting in 250,000 to
43 500,000 fatal cases annually in developing countries (World Health Organization, 2017a).
44 Furthermore, hemagglutinin (HA) and neuraminidase (NA) surface protein combinations are
45 used to characterize influenza viruses. There are 18 HA (H1 – H18) and 11 NA (N1 – N11)
46 subtypes, respectively. Of these subtypes, H5 and H7 are of major concern within the scientific
47 community; as they manifest as low pathogenic infections in waterfowl, which can become
48 highly pathogenic when introduced to domestic poultry, and are zoonotic. (Canadian Food
49 Inspection Agency, 2015; Centers for Disease Control and Prevention, 2017, 2015; Health
50 Canada, 2008; Jensen et al., 2013; Olsen et al., 2006; World Health Organization, 2017b; Zhu
51 et al., 2014). Consequently, governments and farmers alike are under immense pressure to
52 ensure the health of poultry and poultry consumers.

53

54 Preventing the spread of avian influenza infection is the best way to keep disease outbreaks
55 under control. Prevention starts with effective bio-surveillance through early disease diagnosis.
56 To date there are no pen-side or coop-side tests available for rapid diagnosis. Conventional
57 methods of avian influenza detection include one-step reverse transcription polymerase chain
58 reaction (RT-PCR), hemagglutinin inhibition tests, enzyme-linked immunosorbent assay

59 (ELISA), embryonated egg virus culturing, and chicken pathogenicity tests (Jensen et al., 2013;
60 United States Department of Agriculture, 2015; World Organization for Animal Health, 2016).

61

62 In the United States, tests carried out by the National Animal Health Laboratory Network
63 (NAHLN) (United States Department of Agriculture, 2015) are as follows: matrix screening
64 for AI viruses, H5 subtype screening, H7 subtype screening, and N1 subtype screening; all of
65 which are RT-PCR based tests (American Plant Health Inspection Service, 2008; United States
66 Department of Agriculture, 2015). These tests are followed by three types of confirmatory tests:
67 virus isolation tests (in embryonated eggs), genetic sequencing tests, and chicken pathogenicity
68 tests. The test samples are usually obtained from fecal or tracheal swabs from live specimens.
69 Typically these tests take 2-3 weeks to run, require expensive equipment, and require highly
70 trained technicians (American Plant Health Inspection Service, 2008).

71

72 To overcome the obstacles of poor diagnostic turnaround and the need for specialized
73 facilities, research has been moving towards virus detection on the nanoscale using point-of-
74 care (POC) biosensors (Neethirajan et al., 2017). The major benefits of nanoscale virus
75 detection include: a significant reduction in reaction time due to increased surface area for the
76 reaction to take place; and a significant reduction in the costs of testing (e.g. reagent costs,
77 personnel costs, facility costs, and transportation costs). Due to the current technology
78 limitations, this work will focus on bridging the gap through the design of a rapid point-of-care
79 biosensor for the detection of avian influenza A viruses.

80

81 Graphene is an abundant, inexpensive two-dimensional atomic crystal with outstanding
82 physical properties, including extreme mechanical strength, exceptionally high electronic
83 conductivities, superior surface area, and biocompatibility. It is an excellent substrate for

84 biomolecule anchoring and detection due to its surface area of 2630 m²/g¹⁰ and unique sp²
85 (sp²/sp³) bonded network (Hu et al., 2015; Veerapandian and Neethirajan, 2015). In addition,
86 by exploiting the electrochemical properties, graphene can be functionalized easily for
87 developing novel biosensing and transduction mechanisms. Recent graphene-based biosensing
88 platforms developed in our lab and others (Veerapandian et al., 2016a, 2016b; Weng and
89 Neethirajan, 2016) indicate the potential for an electrochemical nanobiosensing platform for
90 virus detection applications.

91
92 In this study, an immunosensor was designed by incorporating gold-graphene
93 nanocomposites, antibody-antigen immunochemistry, and electrochemical quantum dot
94 tagging. The goal of this study was to develop a sensing mechanism that was more sensitive
95 and less time consuming than commercial ELISA. The proposed immunosensor uses a thin
96 film fabricated of gold-graphene nanocomposites on a screen-printed electrode. Virus-specific
97 antibodies were immobilized on the nanocomposite surface using N-(3-dimethylaminopropyl)-
98 N'-ethylcarbodiimide (EDC) and N-hydroxysuccinimide (NHS) carbodiimide chemistry.
99 Cadmium telluride (CdTe) quantum dots were conjugated with virus-specific antibodies in an
100 *in-situ* manner using EDC/NHS chemistry. This sensing mechanism is an immunosensing on
101 a screen-printed electrode, in which the magnitude of the CdTe electrochemical signal is
102 proportional to the antigen concentration. The immunosensor was first designed for H5N1 viral
103 protein as a proof-of-concept. To demonstrate the practicality of the immunosensor for real
104 virus detection, low pathogenic H4N6 spiked in whole chicken blood was studied.

105

106 **2. Materials and methods**

107 *2.1 Materials and reagents*

108 Gold (III) chloride trihydride ($\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$), L-polylysine, hydroquinone, potassium
109 hexacyanoferrate ($\text{K}_4[\text{Fe}(\text{CN})_6]$), potassium hexacyanoferrite ($\text{K}_3[\text{Fe}(\text{CN})_6]$), phosphate buffer
110 saline (PBS), gold cleaning solution, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
111 (EDC), N-hydroxysuccinimide (NHS), CdTe quantum dots and pyrene carboxylic acid were
112 purchased from Sigma-Aldrich (MO, USA). Graphene (4% wt. water dispersion) was obtained
113 from ACS Materials (CA, USA). All the chemicals were of analytical grade and used as
114 received without further purification. Screen-printed gold electrodes were purchased from
115 Dropsens (Spain). Whole chicken blood and influenza virus A (H1N1) surface protein were
116 purchased from Cedarlane Labs (ON, Canada). Anti-influenza A (H5N1) virus hemagglutinin
117 (HA) antibody and influenza virus A (H5N1) surface protein were purchased from Abcam,
118 Inc., (Cambridge, UK). Anti-H4 (H4N6) polyclonal antibody was purchased from
119 MyBioSource Inc., (San Diego, USA). Milli-Q water (18.2 M Ω , DI water) was used throughout
120 the experiments.

121

122 *2.2 Avian influenza (H4N6) and (H9N2) virus cultures*

123 Low pathogenic AIV H4N6 (avian influenza A/Duck/Czech/56 (H4N6)) was propagated in
124 11-day-old embryonated chicken eggs by inoculation into the allantoic cavity (Szretter et al.,
125 2006). Infectious titer in allantoic fluid was determined at 72 h post-inoculation and expressed
126 as a 50% tissue culture infective dose 128 HAU/50 μL .

127

128 Inactivated AIV H9N2 (A/Turkey/Ontario/1/66) was propagated in 11-day-old
129 embryonated SPF chicken eggs. The egg-derived virus was inactivated with formalin (final
130 concentration 0.02%) for 72 h at 37 °C. The protein content of the inactivated virus preparation
131 was determined using haemagglutination inhibition (HI) assay and expressed as 50% tissue
132 culture infective dose 128 HAU/50 μL (Singh et al., 2016).

133 2.3 Fabrication of non-spherical graphene-gold nanocomposites

134 The nanocomposites were synthesized in a one-pot, *in-situ* method resulting in a final
135 working solution volume of 20 mL. First, 18 mL of 40X diluted graphene solution (final
136 solution concentration of 1 mg/mL) was sonicated for 15 minutes to separate the graphene
137 sheets. Next, 1 mL of H_{Au}Cl₄ (final solution concentration of 2.5 x 10⁻⁴ M) was added to the
138 graphene solution under constant stirring. The solution was then stirred for 30 minutes. Next,
139 1 mL of hydroquinone (final solution concentration of 2.5 x 10⁻⁴ M) was added to the graphene
140 gold solution to simultaneously reduce Au³⁺ to Au⁰ and graphene to reduced graphene. The
141 solution was stirred for 1 hour at room temperature to allow complete reduction. The solution
142 was then centrifuged at 15,000 rpm for 5 minutes to remove any unused reactants. The
143 supernatant was removed from each tube, followed by a washing step with DI water. This
144 centrifugation and washing procedure was carried out three times to ensure that any remaining
145 reducing agent had been removed. The solution was then returned to a single 20 mL glass vial
146 after the final washing step. The nanocomposite solution was then stored in a refrigerator at
147 4°C for future use.

148

149 The graphene-Au nanocomposites were characterized using UV-Visible spectroscopy (Cary
150 100, Agilent Technologies), transmission electron microscopy (TEM, FEI Tecnai G2 F20
151 microscope), scanning electron microscopy (SEM), energy dispersive x-ray (EDX) analysis,
152 and electrochemical technique.

153

154 2.4 Nanocomposite deposition on electrodes

155 All electrodes were first cleaned by dropping 10 µL of gold cleaning solution onto the
156 working electrode. After 10 seconds the electrodes were washed thoroughly with DI water.
157 Next, 5 µL of L-polylysine was dropped onto the working electrode and was spread to cover

158 the entire working electrode area. The electrodes were covered in a petri dish dried for 2 hours
159 at room temperature, followed by a DI water rinse to remove any unbound L-polylysine. The
160 same process was carried out for depositing the graphene-Au nanocomposite solution. These
161 alternating layers formed L-polylysine/nanocomposite bilayers on the substrate. Two bilayers
162 were used (meaning 4 layers in total) for the electrochemical immunosensing.

163

164 *2.5 Antibody conjugation*

165 Electrodes were first functionalized by using 1 mM pyrene carboxylic acid (adding a -
166 COOH group to the graphene sheets). 10 μ L of pyrene carboxylic acid was deposited onto each
167 working electrode and the electrodes were set to dry for 1 hour. Next, 5 μ L of 4 mM EDC was
168 deposited onto the working electrodes followed by 5 μ L of 10 mM NHS. The electrodes were
169 left for 10 minutes to allow reaction between EDC and NHS, which was followed by a light DI
170 water wash step to remove any o-acylisourea by-product. Next, 5 μ L of the respective primary
171 antibody, anti-H_x (1 μ g/mL), was deposited onto the working electrode. The electrodes were
172 incubated overnight at 4°C in a moisture chamber.

173

174 CdTe quantum dots were conjugated with anti-N1 antibodies (1 μ g/mL) using the same
175 EDC/NHS carbodiimide crosslinking. The quantum dots were also incubated overnight at 4°C.
176 The same procedures were followed to immobilize Anti-H4 antibodies onto the CdTe quantum
177 dots.

178

179 *2.6 Optimization of AIV immunosensor*

180 The concentration of primary antibodies was tuned by conducting cyclic voltammetry (CV)
181 studies on electrodes with varying antibody concentrations (0.5 μ g/mL to 2.5 μ g/mL). A 1:1
182 mixture of 5 mM of K₄[Fe(CN)₆] and K₃[Fe(CN)₆] in 1X PBS (pH 7.4) was used as the


183 electrolyte solution. During testing 100 μ L of the electrolyte solution was dropped onto the
184 electrode. Antibody concentration that resulted in the lowest current corresponding to highest
185 surface coverage was chosen for the design. A commercial potentiostat (DRP-STAT200,
186 Dropsens, Spain) was used to measure electrochemical redox current at a scan rate of 0.01 V/s.
187 Similarly, a study was conducted using various antibody-antigen interaction times (0 min, 5
188 min, 10 min, 20 min, and 60 min). For this test 5 μ L of target antigen (H4N6) spiked blood
189 dilution was dropped onto each respective electrode, immediately followed by 5 μ L of CdTe
190 anti-H4 bioconjugate. Incubation time was considered to begin after the CdTe bioconjugates
191 were added. After each incubation time period, the electrodes were gently washed with DI
192 water. Each electrode was tested by micropipeting 100 μ L of PBS buffer onto the antibody-
193 antigen-antibody superstructure. The electrochemical redox current of the CdTe quantum dot
194 reporters was measured to obtain applicable incubation time.

195

196 *2.7 Electrochemical immunosensing of AIV*

197 The schematic of electrochemical immunosensing of AIV is illustrated in Fig. 1. Screen-
198 printed gold electrodes were used for these tests. A total of 8 serial dilutions of H5N1 surface
199 protein were used (1 μ g/mL to 1 fg/mL), each concentration was tested in triplicates. Similarly,
200 a total of 8 serial dilutions of H4N6 were used (128 HAU, 1.28 HAU, 1.28 x 10⁻² HAU, 1.28
201 x 10⁻³ HAU, 1.28 x 10⁻⁴ HAU, 1.28 x 10⁻⁵ HAU, 1.28 x 10⁻⁶ HAU, and 1.28 x 10⁻⁷ HAU).
202 H4N6 dilutions were spiked in three-parts diluted whole chicken blood (PBS, pH 7.4). 5 μ L of
203 each viral dilution was dropped onto respective anti-H_x modified working electrode. Next, 5
204 μ L of the anti-N1 (for H5N1) or anti-H4 (for H4N6) conjugated CdTe quantum dots was
205 micropipetted onto each working electrode. In case of H5N1, the electrodes were incubated in
206 a moisture chamber for 1 hr at 4°C to allow for antibody-antigen interaction, which was then
207 followed by a DI water wash to remove any unbound quantum dot reporters. The H4N6 virus

208 was incubated for an optimized duration of 10 minutes. The electrochemical redox current of
209 the CdTe quantum dot reporters was measured with varying antigen concentrations. Each
210 electrode was tested by micropipeting 100 μ L of PBS buffer onto the antibody-antigen-
211 antibody superstructure. All tests were conducted using a scan range of 0.1 V to -1 V with a
212 scan rate of 0.01 V/s and a sampling rate of 0.002 V/s.



213
214 Fig. 1. Electrochemical immunosensing mechanism for direct detection of influenza A virus in
215 a whole chicken blood sample matrix.

216 217 2.8 Specificity and cross reactivity studies

218 The designed immunosensor was tested for specificity to H5N1 and H4N6. This was done
219 by using H1N1 recombinant protein, H9N2 virus, and 1 mg/mL peptidoglycan (dispersion in
220 1X PBS) as negative controls. H5N1 recombinant protein was also used as a negative control
221 for H4N6 virus. The control concentrations used for recombinant proteins and viruses were 1
222 μ g/mL and 128 HAU, respectively. For cross reactivity testing of H4N6 in diluted whole blood,

223 the sample was spiked with 1 mg/mL peptidoglycan and 128 HAU of H4N6. Blanks were also
224 run for both H5N1 and H4N6 as negative controls. These tests were conducted in triplicates.

225

226 *2.9 Validation studies with commercial ELISA*

227 A comparison study was performed with a commercial avian influenza A H4N6 (Cat. No:
228 NS-E10156, Novatein Biosciences, Woburn, MA, USA) ELISA Kit to validate the designed
229 immunosensor. Various virus titers were prepared using sample diluent provided in the ELISA
230 kit box and by strictly following the manufacturer's protocol in the performance of the bioassay.


231

232 **3. Results**

233 *3.1 Nanocomposite characterization*

234 In this study, graphene sheets were decorated with non-spherical nanoparticles in a one-pot
235 *in-situ* simultaneous reduction of graphene and a gold salt using hydroquinone as a reducing
236 agent. TEM images of the fabricated nanostructures can be observed in Fig. 2. From Fig. 2,
237 more particularly panels C and D, it can be confirmed that graphene sheets have been decorated
238 with non-spherical or “spikey” nanoparticles. The resulting nanocomposites were also
239 examined using SEM and EDX to determine their composition (Fig. S1). Through elemental
240 analysis, it was found that C, Au, and O were present in the sample, indicating that the graphene
241 sheets were successfully decorated with gold nanoparticles. This was also confirmed via UV-
242 visible spectroscopic studies (Fig. S2). From Fig. S2, the nanocomposite exhibited the
243 characteristic $\pi - \pi$ bond of the polyaromatic C – C at 230 nm for graphene, as well as a second
244 broad peak that was associated with the gold nanoparticles. It is hypothesized that using
245 hydroquinone as a reducing agent would promote the formation of non-spherical gold
246 nanoparticles on graphene sheets. The reason non-spherical gold nanoparticles were desired

247 was because they would act as excellent spacers between the graphene sheets, thus reducing π
248 $-\pi$ stacking, promoting inter-layer linkage, and increasing the conductivity of graphene.



264 Fig. 2. TEM images of non-spherical graphene-gold nanocomposites. (A) 200 nm scale
265 demonstrates that graphene has been decorated with numerous nanoparticles; (B) 100 nm scale
266 demonstrates non-spherical shape; (C) 20 nm scale depicts a small group of non-spherical
267 nanoparticles as well as detailed graphene sheets; and (D) 10 nm scale depicts a single non-
268 spherical nanoparticle.

269

270 Cyclic voltammetry (CV) studies were conducted to determine the signal amplification due
271 to electrode surface modifications with the developed nanocomposite (Fig. S3). From Fig. S3,

272 it can be observed that each successive bilayer (L-polylysine and nanocomposite) caused an
273 associated response. We found that a single bilayer would sometimes wash away after testing,
274 therefore additional bilayers were needed. The second and third bilayers provided more stable
275 surface modifications while also increasing the measured signal. However, the two bilayer
276 modification was chosen for further experimentation, as it reduced electrode fabrication time,
277 provided a stable modification, and increased the measured signal.

278

279 *3.2 Antibody concentration optimization*

280 Five different antibody concentrations were used to determine an optimum coverage of the
281 working electrode by the primary antibody. The concentration studies can be observed in Fig.
282 S4. The primary antibody concentration with the lowest current value was found to be 1 µg/mL.
283 This was chosen as the standard as experimentation was continued. The same concentration of
284 secondary antibody was used to form CdTe quantum dot bioconjugates.


285 The proposed immunosensor must provide sensing results more rapidly than current
286 conventional methods. In attempt to reduce the time for analysis, antigen – antibody interaction
287 time studies were conducted (Fig. S5). It was found that the highest response is received at an
288 incubation period of 60 minutes. This is on-par with current conventional techniques, however,
289 we wanted a sensor that could be used rapidly in a point-of-care fashion. Therefore, we chose
290 and incubation time of 10 minutes, as it provided the second highest response. An incubation
291 time of 10 minutes is much more feasible than 60 minutes when it comes to point of care device
292 employment. Therefore, an incubation time of 10 minutes was used for the H4N6 study.

293

294 *3.3 H5N1 protein detection in 1X PBS*

295 Detection of H5N1 recombinant protein was used as a proof of concept to determine if the
296 immunosensor mechanism would work. The mechanism was later adapted to detect H4N6

297 virus. The CV profiles of the various H5N1 protein concentrations are shown in Fig. 3(A).
298 Upon conducting H5N1 sensing experiments, two negative characteristic peaks were found in
299 the CV profiles, one at -0.35V and the second at -0.75V, corresponding to the CdTe
300 bioconjugate reporters. It was found that the characteristic peaks at -0.75V were more
301 prominent, and thus were used to obtain the current – antigen concentration data shown in Fig.
302 3(B). Fig. 3(B) shows a near sigmoidal relationship between peak current and recombinant
303 protein concentration. It was found that the biosensor could distinctly detect spiked
304 concentrations of H5N1 protein in 1X PBS (pH 7.4) from 1 $\mu\text{g/mL}$ to 10 fg/mL. A linear range
305 exists between 10 ng/mL and 10 pg/mL of recombinant protein (Fig. 3(B) inset). The
306 coefficient of determination and slope values for this relationship were found to be 0.987 and
307 $0.9242 \mu\text{A} \cdot \text{mL} \cdot \mu\text{g}^{-1}$, respectively.



308


309 Fig. 3: (A) Cyclic voltammetry profiles for H5N1 surface protein concentrations spiked in 1X
310 PBS (pH 7.4) ranging from 0 $\mu\text{g/mL}$ to 1 fg/mL . (B) Calibration curve of H5N1 surface protein
311 immunosensing derived from the CV. Inset: Linear detection range from 10 ng/mL to 10
312 pg/mL .

313

314 3.4 H4N6 virus detection in blood

315 The goal of this study was to develop an immunosensor with the capability to detect avian
316 influenza A (H4N6) virus in whole chicken blood. Upon conducting H4N6 sensing
317 experiments in three-parts diluted whole chicken blood, it was found that the sensor can detect

318 the viru



329

330 Fig. 4: Avian influenza A (H4N6) sensing results in three-parts diluted whole chicken blood.
331 The sensor exhibits a detection range from 128 HAU to 1.28×10^{-7} HAU in blood.

332

333 It can be observed that a linear response exists for concentrations between 128 HAU and 1.28
334 $\times 10^{-7}$ HAU, with a sensitivity of 0.718 $\mu\text{A}/\text{HAU}$ and a coefficient of determination of 0.975.
335 Additionally, selectivity and cross sensitivity tests were conducted for H4N6 (Fig. 5).

336

337

338

339

340

341

342

343

344


345

346

347

348

349



350 Fig. 5: Selectivity and cross-sensitivity results for the developed avian influenza A (H4N6)
351 virus immunosensing. The blank, H1N1 protein, H5N1 protein, peptidoglycan (PG), and H9N2
352 virus signals are statistically indistinguishable, thus, highlighting the selectivity of the
353 immunosensor to the H4N6 antigen. Cross-sensitivity was observed between PG and H4N6
354 virus, however even in the presence of PG, H4N6 could be distinctly detected and measured.

355

356 These results highlight the selectivity of the immunosensor, as non-target viruses and viral
357 proteins were statistically indistinguishable from a blank sample. More importantly, the

358 immunosensor is selective to H4N6 even when exposed to H9N2 avian influenza virus. It can
359 also be seen that there is no cross sensitivity with peptidoglycan, meaning that H4N6 can still
360 be detected in the presence of peptidoglycan. These results suggest that the developed
361 immunosensor is highly specific to H4N6 in whole chicken blood and that the sensor is ultra-
362 sensitive.

363

364 *3.5 Validation with commercial ELISA kit*

365 The sensitivity of the designed immunosensor was compared to those of a commercially
366 available ELISA kit. The ELISA results for H4N6 inactivated protein demonstrate a sensitivity
367 of 0.128 HAU (Fig. S6). Concentrations lower than 0.128 HAU are statistically
368 indistinguishable by the ELISA kit. In comparison, the immunosensor (LOD = 1.28×10^{-7}
369 HAU) was found to be 10^6 times more sensitive than the commercial ELISA kit. Thus, the
370 designed immunosensor exhibits ultra-sensitivity towards H4N6 inactivated virus.

371

372 **4. Discussion**

373 *4.1 Nanocomposite characterization*

374 From TEM images obtained (Fig. 2), it is evident that spikey/star shaped Au nanoparticles
375 were formed. Due to one-pot in-situ nanocomposite synthesis, the Au nanoparticles bind to
376 graphene electrostatically, thus reducing the overall synthesis time. These composites can
377 provide enhanced effective surface area, superior catalytic properties, increased specificity, and
378 limit of detection (LOD) in comparison to using graphene alone (Bai and Shen, 2012). As an
379 example, individual graphene sheets tend to form irreversible clusters due to van der Waals
380 forces and π - π stacking, thereby reducing their electrochemical properties (Stankovich et al.,
381 2007). However, the incorporation of a second phase (i.e. non-spherical gold nanoparticles)
382 provides a nano-spacer, which increases the graphene interlayer distance to minimize

383 clumping. This effectively increases the conductance in two ways: the first being that both
384 sides of graphene sheets are now accessible and the second being the addition of a conductive
385 metal layer (Si and Samulski, 2008; Tien et al., 2010). The non-spherical confirmation will
386 allow for increased surface area contacts between the nanoparticles and graphene sheet layers.
387 Furthermore, nanospacing allows both sides of the graphene sheets to be conductive by
388 reducing $\pi - \pi$ stacking phenomena. The significance of the presented TEM images is that non-
389 spherical Au nanoparticles were formed, and that the graphene sheets were well-decorated with
390 nanoparticles; thus, forming non-spherical graphene – gold nanocomposites.

391

392 *4.2 Antibody concentration optimization*

393 The optimized antibody concentration that was used during testing was 1 $\mu\text{g/mL}$. However,
394 as concentration was increased beyond 1 $\mu\text{g/mL}$, the associated peak current began to increase
395 as well (Fig. S4). This contradicts electrochemical theory because as antibody concentration is
396 increased, impedance of the electrode should also increase, thus reducing the peak current.
397 These results may have been affected by steric hindrance as antibody concentration was
398 increased. It may also be possible that the antibodies agglomerated together at higher
399 concentrations, forming a conductive layer. Further studies are required to confirm whether
400 these phenomena are occurring.

401

402 *4.3 H5N1 surface protein detection in IX PBS*

403 The results obtained from the cyclic voltammetry studies with respect to recombinant
404 protein concentration (Fig. 3(A)) exhibit baseline shifts, which make some higher
405 concentration curves appear to have weaker peaks than some lower concentrations. This could
406 be due to electrode to electrode variation resulting from non-uniform drying rate of
407 nanocomposite. The resultant peak current values were used to develop a strong current –

408 protein concentration relationship. The negative peaks at -0.75 V (Fig. 3) agree with previous
409 work on the electrochemical reporting properties of CdTe (Amelia et al., 2012). The
410 immunosensor possessed a lower LOD of 10 fg/mL and an upper LOD of detection of 1 µg/mL
411 in PBS (pH 7.4) based on the obtained sigmoidal data (Fig. 3(B)). These results are agreeable
412 with previously developed ELISA and nanoenzyme techniques (Ahmed et al., 2017). It is quite
413 possible that the biosensor can detect concentrations greater than 1 µg/mL; however, higher
414 concentrations have yet to be tested. It can be said that the linear concentration range (Fig. 3(B)
415 inset) shows promise of ultra-sensitive detection of the target antigen.

416

417 *4.4 H4N6 inactivated virus detection in blood*

418 The immunosensor demonstrated ultra-sensitive detection of avian influenza A (H4N6) in
419 three-parts diluted whole blood, with an upper and lower LOD of 128 HAU and 1.28×10^{-7}
420 HAU (Fig. 4). The designed immunosensor also exhibited excellent selectivity towards H4N6
421 inactivated virus (Fig. 5). Even in the presence of highly concentrated peptidoglycan, a
422 component of bacterial cell walls, H4N6 could be selectively detected. These results are highly
423 significant because some samples (e.g. blood, faeces, mucosa, and sputum) can contain both
424 viral and bacterial contaminants – it is important to be able to detect the target virus in such
425 complex media. Due to the 10-minute incubation time, the time-to-results have been
426 significantly reduced, when compared to conventional ELISA. Moreover, the immunosensor
427 was 10^6 times more sensitive than the commercial ELISA. To demonstrate the novelty of this
428 sensor, it was also compared with previous works (Table 1).

429

430 Table 1: Comparison of this work to recent electrochemical-based influenza biosensor studies.

Sensor (method)	Mechanism	Antigen(s)	Sample matrix	LOD	Detection range	Reference
Electrochemical Immunosensor (CV, EIS, CA)	SPGE/RGO/CA/Ab/Ag on microfluidic chip	H1N1 virus	PBS	0.5 PFU	1 – 10 ⁴ PFU	(Singh et al., 2017)
Electrochemical Immunosensor (N/A)	SPCE/Ab/BSA/Ag	H1N1 virus	chick embryo allantoic fluid	0.43 HAU	4 – 64 HAU	(Zhang et al., 2017)
Aptamer Sensor (CV, DPV)	SPCE/Au NP/DNA-aptamer/Ag/Ab-ALP	H5N1 protein	PBS	100 fM	100 fM – 10 pM	(Diba et al., 2015)
Electrochemical Immunosensor (DPV)	GCE/Au NP/Ab ₁ /BSA/Ag/Ab ₂ /Pt-pZnO-hemin	Not mentioned	PBS; 10 parts diluted human sera	0.76 pg/mL	0.001 – 60 ng/mL	(Yang et al., 2016)
Electrochemical Immunosensor (EIS, SWV)	SPGE/Au NP/scFV/BSA/Ag-His	H5N1 protein	PBS	0.6 pg/mL	4 – 20 pg/mL	(Góra-sochacka et al., 2016)
Electrochemical Immunosensor (CA)	Au electrode/ZnO NR/Ab ₁ /BSA/Ag/Ab ₂ on microfluidic chip	H1N1 protein; H5N1 protein; H7N9 protein	PBS	1 pg/mL	1 pg/mL – 10 ng/mL	(Han et al., 2016)
Electrochemical Immunosensor (CV, LSV)	Au electrode/ G-Au NP/MAb/Ag/PAb-Ag NP-G	H7 protein	PBS	1.6 pg/mL	1.6 pg/mL – 16 ng/mL	(Huang et al., 2016)
Electrochemical Immunosensor (CV)	SPGE/PL/G-Au NP-Ab/Ag/Ab-CdTe; SPCE/PL/G-Au NP-Ab/Ag/Ab-CdTe	H5N1 protein; H4N6 virus	PBS; 3 parts diluted chicken whole blood	1 fg/mL; 1.28 x 10 ⁻⁷ HAU	1 fg/mL - 1 ug/mL; 1.28 x 10 ⁻⁷ – 128 HAU	This work

431

432 LOD – limit of detection, CV – cyclic voltammetry, EIS – electrochemical impedance spectroscopy, CA – chronoamperometry, DPV –
433 differential pulse voltammetry, SWV – square wave voltammetry, LSV – linear sweep voltammetry, SPGE – screen-printed gold electrode,
434 RGO – reduced graphene oxide, Ab – antibody, Ab₁ – primary antibody, Ab₂- secondary antibody, Ag – antigen, SPCE – screen-printed carbon
435 electrode, NP – nanoparticles, PL – L-polylysine, ALP – alkaline phosphatase, GCE – glassy carbon electrode, BSA – bovine serum albumin,
436 pZnO – porous zinc oxide, scFV – single chain variable fragments, NR – nanorods, G – graphene, Mab – monoclonal antibody, PAb –
437 polyclonal antibody, PBS – phosphate buffer solution, PFU – plaque forming units, HAU – hemagglutinating units.

438 This work is the first to detect real virus culture in a whole chicken blood sample matrix.
439 Majority of the previously reported work first test the target analyte in buffer followed by
440 spiking the target in biological fluid. This leads to inconsistency in results between buffered
441 targets and spiked targets. Moreover, this work has demonstrated lower limits of detection than
442 previously conducted studies. The goal of this design was to develop a sensing mechanism that
443 is more sensitive than conventional ELISA and to reduce the time-to-results – both of which
444 have been successfully accomplished in this study.

445

446 **5. Conclusions**

447 Due to the high virulence and zoonotic potential associated with H5 and H7 avian influenza
448 pathotypes, it is of utmost importance to control outbreaks by reducing diagnostic turnaround.
449 Current methods of detection exhibit many limitations with respect to sample
450 handling/transport, expensive equipment and reagents, poor diagnostic turnaround and the need
451 for specialized facilities. The work presented aims to provide a rapid electrochemical
452 immunosensor that has potential to be used in a POC fashion on-site. The proposed
453 immunosensor could be employed on farms in the form of a portable hand-held device. With
454 such technology, farmers themselves could monitor the health of their flocks by simply taking
455 a droplet of blood from their chickens, placing it onto a pre-coated electrode, and inserting the
456 electrode into a reader.

457 Comparisons between conventional ELISA and recent electrochemical immunosensor
458 studies were conducted. With respect to avian influenza A H5N1 recombinant protein, the
459 immunosensor exhibited a lower LOD of 10 pg/mL and an upper LOD of 10 ng/mL in the linear
460 range; however, a sigmoidal detection range from 10 pg/mL to 1 µg/mL was also established.
461 With Respect to avian influenza A H4N6 virus, the immunosensor exhibited selectivity to
462 H4N6, a lower LOD of 1.28×10^{-7} HAU, and an upper LOD of 128 HAU. In the case of H4N6

463 detection in blood, the immunosensor was found to be 10^6 times more sensitive than its
464 commercial ELISA counterpart. With respect to recent electrochemical immunosensor studies,
465 this work is the first to perform total analysis (optimization and detection) of virus in a whole
466 chicken blood matrix, which is a very complex media. The detection limits were much lower
467 for this study in comparison to recent works. Thus, the designed immunosensor exhibited ultra-
468 sensitivity in comparison to conventional ELISA methods and recent studies. In conclusion,
469 this biosensor design is moving in the direction of rapid POC detection in blood, but this study
470 is just the groundwork for a bigger and brighter future of avian influenza virus detection.

471

472 **Acknowledgments**

473 The authors sincerely thank the Natural Sciences and Engineering Research Council of
474 Canada (400705) and the Ontario Ministry of Agriculture, Food and Rural Affairs for funding
475 this study (298634).

476

477 **6. References**

- 478 Ahmed, S.R., Corredor, J.C., Nagy, É., Neethirajan, S., 2017. Amplified visual
479 immunosensor integrated with nanozyme for ultrasensitive detection of avian influenza
480 virus 1. doi:10.7150/ntno.20758
- 481 Amelia, M., Lincheneau, C., Credi, A., 2012. Chem Soc Rev Electrochemical properties of
482 CdSe and CdTe quantum dots. R. Soc. Chem. 41, 5728–5743. doi:10.1039/c2cs35117j
- 483 American Plant Health Inspection Service, 2008. Avian Influenza Diagnostics and Testing
484 Fact Sheet.
485 https://www.aphis.usda.gov/publications/animal_health/content/printable_version/fs_AI
486 [_diagnostics&testing.pdf](https://www.aphis.usda.gov/publications/animal_health/content/printable_version/fs_AI_diagnostics&testing.pdf)
- 487 Bai, S., Shen, X., 2012. Graphene–inorganic nanocomposites. RSC Adv. 2, 64–98.

- 488 doi:10.1039/c1ra00260k
- 489 Canadian Food Inspection Agency, 2015. Avian Influenza (AI) - What to expect if your
490 animals are infected - Animals - Canadian Food Inspection Agency [WWW Document].
491 URL [http://www.inspection.gc.ca/animals/terrestrial-](http://www.inspection.gc.ca/animals/terrestrial-animals/diseases/reportable/ai/what-to-expect-if-your-animals-are-infected/eng/1334853795705/1334853885674)
492 [animals/diseases/reportable/ai/what-to-expect-if-your-animals-are-](http://www.inspection.gc.ca/animals/terrestrial-animals/diseases/reportable/ai/what-to-expect-if-your-animals-are-infected/eng/1334853795705/1334853885674)
493 [infected/eng/1334853795705/1334853885674](http://www.inspection.gc.ca/animals/terrestrial-animals/diseases/reportable/ai/what-to-expect-if-your-animals-are-infected/eng/1334853795705/1334853885674) (accessed 2.9.17).
- 494 Centers for Disease Control and Prevention, 2017. Avian Influenza A (H7N9) Virus | Avian
495 Influenza (Flu) [WWW Document]. URL [https://www.cdc.gov/flu/avianflu/h7n9-](https://www.cdc.gov/flu/avianflu/h7n9-virus.htm)
496 [virus.htm](https://www.cdc.gov/flu/avianflu/h7n9-virus.htm) (accessed 2.9.17).
- 497 Centers for Disease Control and Prevention, 2015. Highly Pathogenic Avian Influenza A
498 (H5N1) in Birds and Other Animals | Avian Influenza (Flu) [WWW Document]. URL
499 <https://www.cdc.gov/flu/avianflu/h5n1-animals.htm> (accessed 2.9.17).
- 500 Diba, F.S., Kim, S., Jin, H., 2015. Amperometric bioaffinity sensing platform for avian
501 influenza virus proteins with aptamer modified gold nanoparticles on carbon chips 72,
502 355–361. doi:10.1016/j.bios.2015.05.020
- 503 Góra-sochacka, A., Sirko, A., Dehaen, W., Jarocka, U., Radecki, J., Radecka, H., 2016. An
504 electrochemical immunosensor based on a 4, 4 -thiobisbenzenethiol self-assembled
505 monolayer for the detection of hemagglutinin from avian influenza virus H5N1 228, 25–
506 30. doi:10.1016/j.snb.2016.01.001
- 507 Han, J., Lee, D., Hong, C., Chew, C., Kim, T., Jungho, J., 2016. A multi-virus detectable
508 microfluidic electrochemical immunosensor for simultaneous detection of H1N1 , H5N1
509 , and H7N9 virus using ZnO nanorods for sensitivity enhancement. Sensors Actuators B.
510 Chem. 228, 36–42. doi:10.1016/j.snb.2015.07.068
- 511 Health Canada, 2008. Avian Influenza (Bird Flu) Fact Sheet.
- 512 Huang, J., Xie, Z., Xie, Z., Luo, S., Xie, L., Huang, L., Fan, Q., Zhang, Y., Wang, S., Zeng,

- 513 T., 2016. Silver nanoparticles coated graphene electrochemical sensor for the
514 ultrasensitive analysis of avian influenza virus H7. *Anal. Chim. Acta* 913, 121–127.
515 doi:10.1016/j.aca.2016.01.050
- 516 Jensen, T.H., Ajjouri, G., Handberg, K.J., Slomka, M.J., Coward, V.J., Cherbonnel, M.,
517 Jestin, V., Lind, P., Jorgensen, P.H., 2013. An enzyme-linked immunosorbent assay for
518 detection of avian influenza virus subtypes H5 and H7 antibodies. *Acta Vet Scand* 55,
519 84. doi:10.1186/1751-0147-55-84
- 520 Neethirajan, S., Ahmed, S.R., Chand, R., Buoziš, J., Nagy, É., 2017. Recent Advances in
521 Biosensor Development for Foodborne Virus Detection 1. doi:10.7150/ntno.20301
- 522 Olsen, B., Munster, V.J., Wallensten, A., Waldenström, J., Osterhaus, A.D.M.E., Fouchier,
523 R.A.M., 2006. Global patterns of influenza A virus in wild birds. *Science* 312, 384–8.
524 doi:10.1126/science.1122438
- 525 Si, Y., Samulski, E.T., 2008. Exfoliated graphene separated by platinum nanoparticles.
526 *Chem. Mater.* 20, 6792–6797. doi:10.1021/cm801356a
- 527 Singh, R., Hong, S., Jang, J., 2017. Label-free Detection of Influenza Viruses using a
528 Reduced Graphene Oxide-based Electrochemical Immunosensor Integrated with a
529 Microfluidic Platform. *Nat. Publ. Gr.* 2017, 1–11. doi:10.1038/srep42771
- 530 Singh, S., Alkie, T., Abdelaziz, K., Hodgins, D., Novy, A., Nagy, É., Sharif, S., 2016.
531 Characterization of Immune Responses to an Inactivated Avian Influenza Virus
532 Vaccine. *Viral Immunol.* 29, 269–275. doi:10.1089/vim.2015.0144
- 533 Stankovich, S., Dikin, D.A., Piner, R.D., Kohlhaas, K.A., Kleinhammes, A., Jia, Y., Wu, Y.,
534 Nguyen, S.T., Ruoff, R.S., 2007. Synthesis of graphene-based nanosheets via chemical
535 reduction of exfoliated graphite oxide. *Carbon N. Y.* 45, 1558–1565.
536 doi:10.1016/j.carbon.2007.02.034
- 537 Szretter, K.J., Balish, A.L., Katz, J.M., 2006. Influenza: propagation, quantification, and

- 538 storage. *Curr Protoc Microbiol* Chapter 15, Unit 15G 1.
- 539 doi:10.1002/0471729256.mc15g01s3
- 540 Tien, H., Huang, Y., Yang, S., Wang, J., Ma, C.M., 2010. The production of graphene
541 nanosheets decorated with silver nanoparticles for use in transparent , conductive films.
542 *Carbon* N. Y. 49, 1550–1560. doi:10.1016/j.carbon.2010.12.022
- 543 United States Department of Agriculture, 2015. Avian Influenza Testing and Diagnostics
544 Fact Sheet [WWW Document]. USDA Press Off. URL
545 <https://www.usda.gov/documents/usda-avian-influenza-diagnostics-testing-factsheet.pdf>
546 (accessed 2.9.17).
- 547 Veerapandian, M., Hunter, R., Neethirajan, S., 2016a. Lipoygenase-modified Ru-bpy /
548 graphene oxide : Electrochemical biosensor for on-farm monitoring of non-esterified
549 fatty acid. *Biosens. Bioelectron.* 78, 253–258. doi:10.1016/j.bios.2015.11.058
- 550 Veerapandian, M., Hunter, R., Neethirajan, S., 2016b. Dual immunosensor based on
551 methylene blue-electroadsorbed graphene oxide for rapid detection of the in fl uenza A
552 virus antigen. *Talanta* 155, 250–257. doi:10.1016/j.talanta.2016.04.047
- 553 Veerapandian, M., Neethirajan, S., 2015. Graphene oxide chemically decorated with Ag–Ru/
554 chitosan nanoparticles: fabrication, electrode processing and immunosensing properties.
555 *RSC Adv.* 5, 75015–75024. doi:10.1039/C5RA15329H
- 556 Weng, X., Neethirajan, S., 2016. A micro fluidic biosensor using graphene oxide and
557 aptamer- functionalized quantum dots for peanut allergen detection. *Biosens.*
558 *Bioelectron.* 85, 649–656. doi:10.1016/j.bios.2016.05.072
- 559 World Health Organization, 2017a. WHO | Influenza (Seasonal) [WWW Document]. WHO.
560 URL <http://www.who.int/mediacentre/factsheets/fs211/en/> (accessed 3.9.17).
- 561 World Health Organization, 2017b. WHO | Avian and other zoonotic influenza.
- 562 World Organization for Animal Health, 2016. Avian Influenza (Infection with Avian

- 563 Influenza Viruses), in: Manual of Diagnostic Tests and Vaccines for Terrestrial
564 Animals. OIE, pp. 1–23.
- 565 Yang, Z., Zhuo, Y., Yuan, R., Chai, Y., 2016. A nanohybrid of platinum nanoparticles-porous
566 ZnO – hemin with electrocatalytic activity to construct an amplified immunosensor for
567 detection of influenza. Biosens. Bioelectron. 78, 321–327.
568 doi:10.1016/j.bios.2015.10.073
- 569 Zhang, H., Zhang, S., Liu, N., 2017. Prevention and control of emergent infectious disease
570 with high specific antigen sensor. Artif. Cells, Nanomedicine, Biotechnol. 0, 1298–
571 1303. doi:10.3109/21691401.2016.1161638
- 572 Zhu, L., Zhu, C., Deng, G., Zhang, L., Zhao, S., Lin, J., Li, L., Jiao, P., Liao, M., Liu, Y.,
573 2014. Rapid identification of H5 avian influenza virus in chicken throat swab specimens
574 using microfluidic real-time RT-PCR. Anal. Methods 6, 2628. doi:10.1039/c3ay42126k
575